In the first part of her interview with Pharmaceutical Executive, Sandra Coufal, MD, CEO of Toragen, explains why the HPV E5 ...

How existing technologies and approaches such as targeted AI deployment can help make prior authorization workflows more ...

Accelerated approval of sonrotoclax establishes a targeted BCL2 option in post–BTK inhibitor relapsed/refractory mantle cell lymphoma, a setting with limited effective salvage therapies and poor ...

Phase IIIb SURMOUNT-Maintain showed near-complete weight-loss maintenance on maximum tolerated tirzepatide through Week 112, while a 5 mg step-down dose was associated with 5.6 kg mean regain.

Veppanu leverages PROTAC-mediated ubiquitin–proteasome degradation to eliminate mutant estrogen receptor, aiming to bypass ESR1-driven endocrine resistance rather than merely inhibiting receptor ...

Robert F. Kennedy reportedly initiated Makary’s ouster, and the White House signed off, underscoring HHS-driven influence over FDA leadership and the agency’s near-term policy direction. Kyle ...

In today's Pharmaceutical Executive Daily, GSK enters an exclusive collaboration with Sino Biopharmaceutical's CTTQ ...

Deal terms include $2.0 billion upfront and up to $200 million milestone-based consideration, with closing anticipated in ...

Madrigal Pharmaceuticals entered an exclusive global license agreement with Arrowhead Pharmaceuticals for ARO-PNPLA3, a ...

TRuE-AD4 enrolled adults with 10%–20% BSA moderate atopic dermatitis and prior inadequate response, intolerance, or ...

White House sources indicate Trump approved Makary’s removal, reflecting escalating senior leadership churn across federal health agencies. Makary’s tenure featured MAHA-aligned regulatory positions, ...

Consideration is set at $31.50 per Catalyst share in cash, implying an equity value above $4.1 billion and a 21% premium to ...